Company intelligence / Profile preview

Liaoning Yisheng Biopharma Co., Ltd.

Liaoning Province, Chinaliaoningyishengbio.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company has multiple approved prophylactic and therapeutic vaccines. Its lyophilized rabies vaccine has been used by tens of millions in China over more than fifteen years. It holds significant market share in China's rabies vaccine sector. Clinical programs include next-generation rabies and COVID‑19 vaccines using its proprietary PIKA® platform.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Prophylactic vaccinesInactivated vaccinesTherapeutic vaccines
Industry: Biotech

Drug pipeline

5 assets

YSJA rabies vaccine

Commercial

Indications: Rabies

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Liaoning Yisheng Biopharma Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liaoning Yisheng Biopharma Co., Ltd..

Explore the full profile